Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons - PubMed (original) (raw)
Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons
Peter M Clifford et al. Brain Res. 2007.
Abstract
We have investigated the possibility that soluble, blood-borne amyloid beta (Abeta) peptides can cross a defective blood-brain barrier (BBB) and interact with neurons in the brain. Immunohistochemical analyses revealed extravasated plasma components, including Abeta42 in 19 of 21 AD brains, but in only 3 of 13 age-matched control brains, suggesting that a defective BBB is common in AD. To more directly test whether blood-borne Abeta peptides can cross a defective BBB, we tracked the fate of fluorescein isothiocyanate (FITC)-labeled Abeta42 and Abeta40 introduced via tail vein injection into mice with a BBB rendered permeable by treatment with pertussis toxin. Both Abeta40 and Abeta42 readily crossed the permeabilized BBB and bound selectively to certain neuronal subtypes, but not glial cells. By 48 h post-injection, Abeta42-positive neurons were widespread in the brain. In the cerebral cortex, small fluorescent, Abeta42-positive granules were found in the perinuclear cytoplasm of pyramidal neurons, suggesting that these cells can internalize exogenous Abeta42. An intact BBB (saline-injected controls) blocked entry of blood-borne Abeta peptides into the brain. The neuronal subtype selectivity of Abeta42 and Abeta40 was most evident in mouse brains subjected to direct intracranial stereotaxic injection into the hippocampal region, thereby bypassing the BBB. Abeta40 was found to preferentially bind to a distinct subset of neurons positioned at the inner face of the dentate gyrus, whereas Abeta42 bound selectively to the population of large neurons in the hilus region of the dentate gyrus. Our results suggest that the blood may serve as a major, chronic source of soluble, exogenous Abeta peptides that can bind selectively to certain subtypes of neurons and accumulate within these cells.
Similar articles
- Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease.
Matsumoto Y, Yanase D, Noguchi-Shinohara M, Ono K, Yoshita M, Yamada M. Matsumoto Y, et al. Dement Geriatr Cogn Disord. 2007;23(4):241-5. doi: 10.1159/000100019. Epub 2007 Feb 19. Dement Geriatr Cogn Disord. 2007. PMID: 17310121 - Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.
LaRue B, Hogg E, Sagare A, Jovanovic S, Maness L, Maurer C, Deane R, Zlokovic BV. LaRue B, et al. J Neurosci Methods. 2004 Sep 30;138(1-2):233-42. doi: 10.1016/j.jneumeth.2004.04.026. J Neurosci Methods. 2004. PMID: 15325132 - Alpha7 nicotinic acetylcholine receptor expression by vascular smooth muscle cells facilitates the deposition of Abeta peptides and promotes cerebrovascular amyloid angiopathy.
Clifford PM, Siu G, Kosciuk M, Levin EC, Venkataraman V, D'Andrea MR, Nagele RG. Clifford PM, et al. Brain Res. 2008 Oct 9;1234:158-71. doi: 10.1016/j.brainres.2008.07.092. Epub 2008 Aug 3. Brain Res. 2008. PMID: 18708033 - Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.
Donahue JE, Johanson CE. Donahue JE, et al. J Neuropathol Exp Neurol. 2008 Apr;67(4):261-70. doi: 10.1097/NEN.0b013e31816a0dc8. J Neuropathol Exp Neurol. 2008. PMID: 18379441 Review. - The killing of neurons by beta-amyloid peptides, prions, and pro-inflammatory cytokines.
Chiarini A, Dal Pra I, Whitfield JF, Armato U. Chiarini A, et al. Ital J Anat Embryol. 2006 Oct-Dec;111(4):221-46. Ital J Anat Embryol. 2006. PMID: 17385278 Review.
Cited by
- Post-translational modifications of beta-amyloid alter its transport in the blood-brain barrier in vitro model.
Varshavskaya KB, Petrushanko IY, Mitkevich VA, Barykin EP, Makarov AA. Varshavskaya KB, et al. Front Mol Neurosci. 2024 Mar 7;17:1362581. doi: 10.3389/fnmol.2024.1362581. eCollection 2024. Front Mol Neurosci. 2024. PMID: 38516041 Free PMC article. - A Chronic Increase in Blood-Brain Barrier Permeability Facilitates Intraneuronal Deposition of Exogenous Bloodborne Amyloid-Beta1-42 Peptide in the Brain and Leads to Alzheimer's Disease-Relevant Cognitive Changes in a Mouse Model.
Acharya NK, Grossman HC, Clifford PM, Levin EC, Light KR, Choi H, Swanson Ii RL, Kosciuk MC, Venkataraman V, Libon DJ, Matzel LD, Nagele RG. Acharya NK, et al. J Alzheimers Dis. 2024;98(1):163-186. doi: 10.3233/JAD-231028. J Alzheimers Dis. 2024. PMID: 38393907 Free PMC article. - The origin and nature of the complex autoantibody profile in cerebrospinal fluid.
Kheirkhah R, DeMarshall C, Sieber F, Oh E, Nagele RG. Kheirkhah R, et al. Brain Behav Immun Health. 2019 Dec 27;2:100032. doi: 10.1016/j.bbih.2019.100032. eCollection 2020 Feb. Brain Behav Immun Health. 2019. PMID: 38377421 Free PMC article. - Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation.
Bauer-Smith H, Sudol ASL, Beers SA, Crispin M. Bauer-Smith H, et al. Biochim Biophys Acta Gen Subj. 2023 Nov;1867(11):130448. doi: 10.1016/j.bbagen.2023.130448. Epub 2023 Aug 29. Biochim Biophys Acta Gen Subj. 2023. PMID: 37652365 Free PMC article. Review. - A Preliminary Report: The Hippocampus and Surrounding Temporal Cortex of Patients With Schizophrenia Have Impaired Blood-Brain Barrier.
Goldwaser EL, Swanson RL 2nd, Arroyo EJ, Venkataraman V, Kosciuk MC, Nagele RG, Hong LE, Acharya NK. Goldwaser EL, et al. Front Hum Neurosci. 2022 Mar 31;16:836980. doi: 10.3389/fnhum.2022.836980. eCollection 2022. Front Hum Neurosci. 2022. PMID: 35431844 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources